Homocysteine: Normal Range, Cardiovascular Risk, Why Lowering It May Not Help

Homocysteine sits at the crossroads of two B-vitamin–dependent pathways:

• Remethylation: homocysteine becomes methionine again, requiring folate (specifically 5-methyltetrahydrofolate) and B12.
• Transsulfuration: homocysteine becomes cysteine, requiring B6 and the enzyme cystathionine beta-synthase (CBS).

Anything that disrupts either pathway raises homocysteine:

• Folate deficiency.
• B12 deficiency.
• B6 deficiency (rarely clinically significant on its own).
• MTHFR polymorphisms (mild) or homozygous CBS deficiency (severe homocystinuria, often above 100 µmol/L).
• Kidney disease. Homocysteine is partly cleared by the kidneys.
• Hypothyroidism. Drugs (methotrexate, phenytoin, metformin, fibrates). Aging.

Sample handling matters more than people realize. Homocysteine keeps leaking out of red cells if the tube sits at room temperature, falsely raising the result. Get the sample on ice or processed within 30–60 minutes. Fasting is preferred.

Conventional adult cutoffs:

• Below 10 µmol/L: optimal.
• 10–15 µmol/L: upper end of normal. Worth checking B-vitamin status if borderline.
• 15–30 µmol/L: mild hyperhomocysteinemia. Check folate, B12, B6, kidney function, TSH.
• 30–100 µmol/L: moderate. Usually B12 or folate deficiency, kidney disease, or compound MTHFR/CBS variants.
• Above 100 µmol/L: severe. Suggests homocystinuria (homozygous CBS deficiency) or profound B12 deficiency. Refer to genetics or hematology.

Levels rise with age and run slightly higher in men than premenopausal women. Pregnancy lowers homocysteine modestly. Don't over-interpret a single mildly elevated value. Repeat under controlled conditions (fasting, prompt sample handling) before labeling someone hyperhomocysteinemic.

Elevated homocysteine has two interpretive layers: what it tells you about B-vitamin status, and what it implies for cardiovascular risk.

What it directly indicates:

• B12 or folate deficiency: the most common explanation. A sensitive functional marker, especially when serum B12 sits in the gray zone (200–300 pg/mL).
• Kidney disease: clearance falls with eGFR. Moderate elevations (15–30 µmol/L) are common in CKD.
• MTHFR polymorphisms: common heterozygous variants raise homocysteine modestly. Homozygous severe variants more so.
• Hypothyroidism: usually resolves with thyroid hormone replacement.
• Drugs: methotrexate, phenytoin, theophylline, metformin (via B12 effect), nitrous oxide (acutely, via B12 inactivation).
• Homocystinuria: autosomal recessive CBS deficiency. Rare. Presents in childhood with lens dislocation, marfanoid habitus, vascular events, intellectual disability.

What it implies for cardiovascular risk: observational studies tie elevated homocysteine to coronary heart disease, stroke, venous thromboembolism, and dementia. The randomized trials of B-vitamin therapy lowered homocysteine and did not reduce cardiovascular events:

• HOPE-2 (2006): 5,522 patients with vascular disease or diabetes. B-vitamins reduced homocysteine, did not reduce major cardiovascular events.
• VISP (2004): stroke prevention. No benefit on recurrent stroke.
• NORVIT (2006): post-MI patients. Some signals of harm with combination therapy.
• SEARCH (2010): 12,064 MI survivors. Folic acid plus B12 did not reduce vascular events.

The most likely explanation: homocysteine flags the underlying B-vitamin deficiency or kidney disease, but isn't itself the proximate cause of vascular injury. Treating high homocysteine to a target with B-vitamins is not currently recommended for cardiovascular risk reduction.

Rarely a problem. Levels below 5 µmol/L turn up in:

• Pregnancy (especially second and third trimester).
• High folate or B12 supplementation.
• Hyperthyroidism.
• Certain drugs (oral contraceptives, hormone therapy).

None of these warrant action based on the homocysteine value alone. No convincing evidence that very low homocysteine is harmful.

Three patterns to recognize:

• Elevated homocysteine + low B12 or low/borderline folate: confirms functional B-vitamin deficiency. Treat the deficiency, recheck homocysteine and B-vitamin levels in 8–12 weeks. Expect a sharp drop.
• Elevated homocysteine + normal B12, folate, B6 + reduced eGFR: likely renal contribution. Manage the kidney disease. B-vitamin supplementation is unlikely to change cardiovascular outcomes.
• Elevated homocysteine + normal B-vitamins + normal kidney function: consider MTHFR genotype, hypothyroidism, drug effects. Severe persistent elevations warrant genetics referral for homocystinuria, especially with personal or family history of premature thrombosis.

Sample handling problems are a frequent cause of artifactually high homocysteine. If a single high result doesn't fit clinically, repeat with a fresh sample on ice and processed promptly.

• Suspected B12 or folate deficiency with borderline B12 (200–300 pg/mL): homocysteine confirms functional deficiency. Treat the underlying deficiency, expect homocysteine to fall.
• Unexplained venous thromboembolism in a young patient: moderate-to-severe hyperhomocysteinemia can be part of a hypercoagulable workup, particularly if homocystinuria is in the differential.
• Young patient with premature atherosclerosis: homocysteine can flag homocystinuria. Consider genetics if persistently above 30–50 µmol/L without B-vitamin deficiency.
• Pregnancy loss or pre-eclampsia history: homocysteine and B-vitamin status are part of the recurrent pregnancy loss workup. Folate optimization is reasonable.
• Routine cardiovascular risk screening: not recommended. Lipids, blood pressure, smoking status, and ApoB do far more to guide management.

If homocysteine is elevated and a B-vitamin deficiency is found, fix it. If it's elevated without a clear deficiency or kidney explanation, don't chase the number with B-vitamins for cardiovascular reasons. The trials have repeatedly shown that doesn't help.

• Vitamin B12: homocysteine rises in B12 deficiency and is a sensitive functional marker.
• Folate: homocysteine also rises in folate deficiency. Check both together.
• Methylmalonic acid (MMA): separates B12 deficiency (high MMA) from isolated folate deficiency (normal MMA).
• Creatinine and eGFR: kidney function is a common cause of moderate hyperhomocysteinemia.
• TSH: hypothyroidism raises homocysteine.
• LDL cholesterol and ApoB: far more actionable cardiovascular risk markers.
• Lipoprotein(a) and hs-CRP: modern adjunctive cardiovascular risk markers with stronger trial support than homocysteine.